No, Abrupt Discontinuation of Tirzepatide Does Not Cause Arthralgia in Multiple Joints
There is no evidence that abrupt stoppage of tirzepatide causes joint pain in multiple sites. The available evidence does not support a causal relationship between tirzepatide discontinuation and the development of arthralgia.
What Actually Happens When Tirzepatide is Stopped
The most recent 2025 American Association of Clinical Endocrinology guidelines 1 and 2025 Endocrine Society guidelines 2 clearly outline the actual consequences of tirzepatide discontinuation:
Primary concerns include:
- Hyperglycemia and weight regain - not joint pain 2
- Rebound weight gain (documented in real-world studies) 3, 4
- Deterioration of cardiometabolic risk factors 3
- Potential cardiovascular risk from loss of metabolic benefits 3
Why Joint Pain is Not Listed as a Withdrawal Effect
The 2025 AACE consensus statement 1 extensively discusses tirzepatide side effects and discontinuation management. Joint pain is conspicuously absent from any discussion of withdrawal symptoms. The guideline emphasizes:
- Gastrointestinal side effects during dose escalation (not withdrawal)
- Need to restart at low doses after treatment pauses
- Monitoring for dehydration and renal impairment during active treatment
Important Distinction: Corticosteroid Withdrawal vs. Tirzepatide Withdrawal
Do not confuse this with corticosteroid withdrawal arthralgia, which is a well-documented phenomenon. The 2025 British Society of Gastroenterology guidelines on autoimmune hepatitis 5 and 2002 hepatology guidelines 6 clearly describe that:
- Joint pains occur in approximately 50% of patients during steroid withdrawal 5
- These arthralgias typically respond to paracetamol or NSAIDs 5, 6
- This is a completely different mechanism from GLP-1 receptor agonist discontinuation
Real-World Discontinuation Data
Recent 2025-2026 studies examining actual reasons for tirzepatide discontinuation 7, 4 found:
Most common reasons for stopping:
- Cost/insurance issues (47.6-80.7%)
- Intolerable side effects (14.6%)
- Medication shortages (11.8%)
- Inadequate weight loss (2.4%)
Notably absent: Joint pain or arthralgia as a reason for discontinuation or as a consequence of stopping.
Clinical Bottom Line
If a patient develops polyarticular joint pain after stopping tirzepatide, look for alternative explanations:
- Coincidental inflammatory arthritis
- Weight regain causing mechanical joint stress
- Unrelated autoimmune condition
- Medication changes (particularly if corticosteroids were involved)
- Pre-existing osteoarthritis becoming symptomatic with weight changes
The evidence shows tirzepatide may actually reduce osteoarthritis risk during treatment 8, making post-discontinuation arthralgia even less biologically plausible as a withdrawal phenomenon.